If your mood changed after menopause, testosterone can sound tempting because it is marketed as energy, drive, and confidence in one hormone.
The evidence is narrower. The 2019 Global Consensus Position Statement says the evidence-based indication for testosterone therapy in women is hypoactive sexual desire disorder, in postmenopausal women after appropriate assessment. [1]
That does not mean mood symptoms are unreal. It means testosterone should not become the shortcut diagnosis.
Does testosterone cause anxiety after menopause?
The evidence does not support a simple yes or no answer. Testosterone is not established as a standard anxiety treatment for women after menopause, and anxiety that appears during midlife should be evaluated on its own. At the same time, physiologic testosterone therapy for selected women is not automatically an anxiety cause.
The clinically useful question is narrower: did anxiety start after a dose change, with supraphysiologic exposure, with pellets or unclear compounded dosing, with sleep disruption, with hot flashes, with a medication change, or with another medical driver? Those patterns change the next step.
That answer is less clickable than "testosterone fixes anxiety" or "testosterone causes anxiety." It is also safer. Mood symptoms deserve their own assessment instead of being forced into a testosterone story.
The strongest evidence is for low desire with distress
A 2019 systematic review and meta-analysis searched blinded randomized trials of testosterone therapy lasting at least 12 weeks. It found 46 reports from 36 randomized controlled trials with 8,480 participants. [2]
The sexual-function signals were clearer than the mood signals. In postmenopausal women, testosterone increased satisfactory sexual event frequency by a mean difference of 0.85 and improved desire, arousal, orgasm, responsiveness, self-image, sexual concerns, and distress compared with placebo or comparator therapy. [2]
That is why the testosterone conversation for women starts with hypoactive sexual desire disorder, not with vague fatigue, anxiety, or brain fog.
Evidence-limit table
| Claim | Evidence posture | Safer framing |
|---|---|---|
| "Testosterone treats anxiety." | Not established as an anxiety indication for women. | Evaluate anxiety on its own before a hormone explanation. |
| "Testosterone fixes brain fog." | A 2025 retrospective pilot reported cognition improvement, but it was not randomized. [4] | Treat as research interest, not an established cognitive therapy. |
| "Testosterone improves low desire." | Consensus and randomized-trial evidence are strongest for postmenopausal hypoactive sexual desire disorder after assessment. [1] [2] | Consider only when low desire is persistent, distressing, and not better explained. |
| "More testosterone means more energy." | The guideline frame is dosing and monitoring, not chasing high levels. [3] | Keep any prescription physiologic and monitored. |
Mood data exists, but it is not settled enough
A 2025 retrospective pilot study from a specialist menopause clinic followed 510 peri- and postmenopausal women using hormone replacement therapy who had persistent low libido, cognitive symptoms, and negative mood symptoms. After 4 months of testosterone cream or gel, 47% reported mood improvement and 39% reported cognition improvement. Mean mood symptom scores decreased by 34%, and mean cognition symptom scores decreased by 22%. [4]
That is interesting. It is not the same as a randomized, placebo-controlled indication.
The authors themselves called for randomized clinical trials to establish long-term efficacy and safety for menopausal cognitive and psychological symptoms. [4]
A separate 8-week randomized placebo-controlled trial tested adjunctive transdermal testosterone in 101 women, ages 21 to 70, with antidepressant-resistant major depressive disorder. Depression scores improved in both groups, but testosterone was not more effective than placebo for depression, fatigue, or sexual function. [5]
In women with primary ovarian insufficiency, a 12-month randomized trial of 128 women found that physiologic testosterone added to estrogen/progestin therapy did not improve quality of life, self-esteem, or mood measures compared with placebo. [6] That population is not the same as natural menopause after 45, but it is another caution against turning low androgen levels into a mood diagnosis.
A 2026 retrospective cohort from a UK specialist menopause clinic reported mood improvement after initiation or optimization of menopausal hormone therapy, including some regimens with testosterone. But testosterone did not clearly separate from estradiol-based optimization in the reported regimen comparisons, and the authors called for prospective randomized trials. [7]
This is the exact place where clinical framing needs discipline. A pilot can justify research interest and careful discussion. It should not become "testosterone treats anxiety."
Anxiety, depression, and brain fog need their own workup
Midlife mood symptoms can come from many sources. Hot flashes can break sleep. Genitourinary symptoms can strain sex and relationships. Thyroid disease, anemia, alcohol, medications, grief, caregiving pressure, depression, anxiety disorders, ADHD, sleep apnea, and insulin resistance can all look like hormone trouble.
Testosterone can also cause side effects. The 2019 meta-analysis found higher reporting of acne and hair growth with testosterone. Oral testosterone had less favorable lipid effects, while non-oral routes were preferred in the review. [2]
The International Society for the Study of Women's Sexual Health guideline focuses on identifying appropriate hypoactive sexual desire disorder patients, baseline testing, dosing, monitoring, and follow-up. [3]
The Endocrine Society guideline is even more explicit about boundaries: it recommends against diagnosing a broad androgen-deficiency syndrome in healthy women and against general testosterone use for cognitive, cardiovascular, metabolic, bone, or general well-being indications. [8]
Decision table: when mood symptoms belong in the testosterone visit
| Decision point | Better fit for testosterone review | Avoid or pause |
|---|---|---|
| Main symptom | Persistent low desire with distress after menopause, after biopsychosocial assessment. | Anxiety, depression, brain fog, fatigue, confidence, or weight as the main goal. |
| Mood context | Mood symptoms are documented, but low desire remains the treatment target. | Testosterone is framed as the primary anxiety or depression treatment. |
| Exposure | Non-oral, physiologic dosing with clear baseline and follow-up monitoring. | Pellets, supraphysiologic dosing, or unclear compounded dosing. |
| Workup | Sleep, hot flashes, genitourinary syndrome of menopause, pain, medications, thyroid disease, anemia, alcohol, and mental-health history are reviewed. | A single low testosterone result is treated as the explanation. |
| Stop rule | No meaningful desire/distress benefit or androgen side effects leads to reassessment. | Dose keeps increasing to chase energy or mood. |
Where testosterone fits
Testosterone can belong in care when low desire is persistent, distressing, and not better explained by pain, vaginal dryness, relationship context, medication effects, untreated mood disorder, or another medical issue.
It does not belong as a broad hormone answer for anxiety after menopause.
Who this fits
Testosterone review may fit a postmenopausal woman whose main concern is persistent low sexual desire with distress after a biopsychosocial assessment. It is a weaker fit when the main concern is panic, depression, trauma, insomnia, untreated pain, relationship distress, thyroid disease, anemia, or medication side effects.
Women should avoid rushing into testosterone when the offer is framed as a broad mood, anxiety, cognition, or vitality fix. That framing outruns the evidence base.
Red flags and safety checks
Red flags include panic symptoms that are new or severe, suicidal thoughts, mania or hypomania symptoms, severe insomnia, chest pain, neurologic symptoms, untreated sleep apnea, heavy alcohol use, abrupt psychiatric-medication changes, or mood symptoms that started after testosterone dose escalation.
Testosterone-specific red flags include acne, unwanted facial hair, scalp hair loss, voice change, clitoral symptoms, supraphysiologic blood levels, pellet dosing that cannot be adjusted quickly, unclear compounded dosing, abnormal lipids, liver disease complexity, and no documented stop rule.
| Safety check | Why it matters |
|---|---|
| Mood and anxiety history | Testosterone should not replace evaluation for depression, anxiety disorders, bipolar disorder, trauma, or medication withdrawal. |
| Sleep and hot flashes | Night sweats, insomnia, alcohol, sleep apnea, and pain can drive anxiety-like symptoms. |
| Medication list | selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors, stimulants, steroids, thyroid medicine, sleep medicines, and recent changes can affect mood, libido, or anxiety. |
| Androgen side effects | Acne, hirsutism, scalp hair loss, voice change, and clitoral symptoms can signal excessive exposure. |
| Dose form | Pellets and unclear compounded products make dose adjustment and monitoring harder. |
| Stop rule | A careful plan says when to reduce, stop, or redirect treatment if mood, desire, or side effects do not improve. |
What to ask a clinician
Ask:
- Is the main problem desire, mood, sleep, cognition, or energy?
- Is there distress from low desire after biopsychosocial assessment?
- Are genitourinary syndrome of menopause, pain with sex, depression, anxiety, thyroid disease, anemia, sleep apnea, or medication effects contributing?
- If testosterone is used, is the route non-oral, the dose physiologic, and the monitoring plan clear?
- What would count as a red flag, excessive exposure, or a reason to stop?
That protects both sides of the question. Women with true hypoactive sexual desire disorder can get evidence-based review, while women with anxiety or mood symptoms do not get routed into the wrong treatment story.
Bottom line
Testosterone after menopause is not a mood supplement.
It is a prescription hormone with a narrow evidence base, real monitoring needs, and a stronger case for hypoactive sexual desire disorder than for anxiety, depression, brain fog, or general vitality.
Related reading:
- Testosterone for Women After Menopause Has One.
- Testosterone Gel for Women After Menopause.
- Testosterone Monitoring for Women.
References
[1] Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Climacteric. 2019;22(5):429-434. doi:10.1080/13697137.2019.1637079 https://pubmed.ncbi.nlm.nih.gov/31474158/
[2] Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-766. doi:10.1016/s2213-8587(19)30189-5 https://pubmed.ncbi.nlm.nih.gov/31353194/
[3] Parish SJ, Simon JA, Davis SR, et al. International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. J Sex Med. 2021;18(5):849-867. doi:10.1016/j.jsxm.2020.10.009 https://pubmed.ncbi.nlm.nih.gov/33814355/
[4] Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Arch Womens Ment Health. 2025;28(3):541-550. doi:10.1007/s00737-024-01513-6 https://pubmed.ncbi.nlm.nih.gov/39283522/
[5] Dichtel LE, Carpenter LL, Nyer M, et al. Low-Dose Testosterone Augmentation for Antidepressant-Resistant Major Depressive Disorder in Women: An 8-Week Randomized Placebo-Controlled Study. Am J Psychiatry. 2020;177(10):965-973. doi:10.1176/appi.ajp.2020.19080844 https://pubmed.ncbi.nlm.nih.gov/32660299/
[6] Guerrieri GM, Martinez PE, Klug SP, et al. Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian insufficiency. Menopause. 2014;21(9):952-61. doi:10.1097/gme.0000000000000195 https://pubmed.ncbi.nlm.nih.gov/24473536/
[7] Glynne S, Kamal A, McColl L, et al. Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort study. Br J Psychiatry. 2026;228(5):409-418. doi:10.1192/bjp.2025.101 https://pubmed.ncbi.nlm.nih.gov/40519046/
[8] Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260 https://pubmed.ncbi.nlm.nih.gov/25279570/